ViaDerma, Inc. Commences First Manufacturing Run and will Meet t
LOS ANGELES, CA--(Marketwired - June 12, 2017) - ViaDerma, Inc. (OTC PINK: VDRM), a specialty pharmaceutical company devoted to bringing new products to market, recently announced today that the Company has commenced manufacturing of its FDA registered topical antibiotic. ViaDerma, Inc. has completed the quality control and approved labeling for the product and will begin distribution of the wound care drug in June. The "Quality Control" plan has been executed and now meets the strict guidelines starting with the manufacturer all the way through to the point of purchase. To assure a solid growth strategy, the Company's go to market expert and strategist, Ivan Klarich, has just returned from multi country Asian tour for ViaDerma where the product was well received. The Company is expecting several countries to order 10,000 units to begin the product launch in several Asian countries. The Company plans to continue to add additional products and offer those new products directly to the same distributors. The Company plans to announce additional new products for its proprietary specialty pharmaceutical product line in the very near future.
The Company's President, Dr. Christopher Otiko, said, "We are all pleased to have a product in manufacturing and to meet our goals. Our product manufacturer will be able to manufacture most of our products and we look forward to building a lasting relationship to deliver high quality pharmaceuticals to our distributors. Since my presentation at DFCON or the Diabetic Foot Global Conference in Houston, TX, in March, we have had a tremendous amount of interest in our topical antibiotic. Our goal is to have our product added to all diabetic foot ulcer treatment protocols around the globe."
About ViaDerma, Inc.
ViaDerma, Inc. (OTC PINK: VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative technology to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. ViaDerma's lead product, a tetracycline-based topical antibiotic, uses an innovative transdermal delivery method that allows for application of active ingredients in a topical form. This patent-pending dual carrier transdermal technology may be applied in products within the medical and cosmetic markets. Also, a patent application using the combination of CBD's and THC with the delivery system was filed in 2017. The use of CBD's is for the reduction of inflammation and for the treatment of several diseases, such as, nicotine addiction, fibromyalgia, Cohn's disease, schizophrenia, migraine headaches, pain management for cancer and Multiple Sclerosis. For more information, please visit: www.viadermalicensing.com
Forward Looking Statements
Forward-Looking Statements certain statements in this release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be identified using words such as "anticipate," "believe," "expect," "future," "may," "will," "would," "should," "plan," "projected," "intend," and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements. The Company's future operating results are dependent upon many factors, including but not limited to the Company's ability to: (i) obtain sufficient capital or a strategic business arrangement to fund its expansion plans; (ii) build the management and human resources and infrastructure necessary to support the growth of its business; (iii) competitive factors and developments beyond the Company's control; and (iv) other risk factors. We assume no obligation to update the information contained in this news release.
The Company's President, Dr. Christopher Otiko, said, "We are all pleased to have a product in manufacturing and to meet our goals. Our product manufacturer will be able to manufacture most of our products and we look forward to building a lasting relationship to deliver high quality pharmaceuticals to our distributors. Since my presentation at DFCON or the Diabetic Foot Global Conference in Houston, TX, in March, we have had a tremendous amount of interest in our topical antibiotic. Our goal is to have our product added to all diabetic foot ulcer treatment protocols around the globe."
About ViaDerma, Inc.
ViaDerma, Inc. (OTC PINK: VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative technology to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. ViaDerma's lead product, a tetracycline-based topical antibiotic, uses an innovative transdermal delivery method that allows for application of active ingredients in a topical form. This patent-pending dual carrier transdermal technology may be applied in products within the medical and cosmetic markets. Also, a patent application using the combination of CBD's and THC with the delivery system was filed in 2017. The use of CBD's is for the reduction of inflammation and for the treatment of several diseases, such as, nicotine addiction, fibromyalgia, Cohn's disease, schizophrenia, migraine headaches, pain management for cancer and Multiple Sclerosis. For more information, please visit: www.viadermalicensing.com
Forward Looking Statements
Forward-Looking Statements certain statements in this release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be identified using words such as "anticipate," "believe," "expect," "future," "may," "will," "would," "should," "plan," "projected," "intend," and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements. The Company's future operating results are dependent upon many factors, including but not limited to the Company's ability to: (i) obtain sufficient capital or a strategic business arrangement to fund its expansion plans; (ii) build the management and human resources and infrastructure necessary to support the growth of its business; (iii) competitive factors and developments beyond the Company's control; and (iv) other risk factors. We assume no obligation to update the information contained in this news release.